FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103245862> ?p ?o ?g. }

• W2103245862 endingPage "3550" @default.
• W2103245862 startingPage "3545" @default.
• W2103245862 abstract "The pathogenesis of hypercalcemia of malignancy comprises increased net bone resorption and enhanced renal tubular reabsorption of calcium (Ca). To evaluate the prevalence of an increased renal tubular reabsorption of Ca index [tubular reabsorption of calcium index (TRCaI)] in cancer patients with hypercalcemia and of elevated circulating levels of PTH-related protein (PTHrP), which is recognized as a major mediator of this syndrome, we investigated 315 well rehydrated patients, aged 58.1 +/- 0.7 yr (mean +/- SEM), with hypercalcemia [albumin-corrected plasma Ca (pCa), >2.7 mmol/L] secondary to histologically proven malignancy. Changes in pCa and, therefore, various Ca filtered loads were obtained by different degrees of bone resorption inhibition achieved with a single infusion of the bisphosphonate ibandronate, given at various doses on a randomized, double blind basis. PTHrP was determined at baseline in 147 of the patients and 7 days after bisphosphonate therapy in 73. Before ibandronate therapy, pCa was 3.36 +/- 0.02 mmol/L, mean TRCaI was increased at 3.09 +/- 0.03 mmol/L glomerular filtration rate (GFR; normal, 2.40-2.90), and 65% of patients had TRCaI above 2.90 mmol/L GFR. Mean serum PTHrP levels were 4.9 +/- 0.5 pmol/L (normal, <2.5) and values above the normal range were found in 53% of the patients (76% in lung and upper respiratory tract malignancies). By 7 days after the infusion of ibandronate, a decrease in pCa of 0.69 +/- 0.03 mmol/L (20.0 +/- 0.7%; P < 0.001) and in bone resorption [mean change in fasting urinary Ca, 0.09 +/- 0.04 mmol/L GFR (47.6 +/- 8.6%; P < 0.001) and 14.4 +/- 1.7 nmol/mmol (27.6 +/- 10.6%; P < 0.01) in deoxypyridinoline] was observed. TRCaI was slightly lowered by 0.30 +/- 0.09 mmol/L GFR. Mean changes in PTHrP, 1,25-dihydroxyvitamin D3, and PTH were +0.7 +/- 0.4 (P = NS), +27.6 +/- 3.0 (P < 0.001), and +2.9 +/- 0.8 (P < 0.005) pmol/L, respectively. After ibandronate treatment, the relative risk of relapsing hypercalcemia was particularly increased (3.43-fold) in lung and upper respiratory tract malignancies. These results obtained in a large cohort of patients indicate a significant prevalence of an increased renal tubular reabsorption of calcium index in hypercalcemia of malignancy and a substantial proportion of patients with detectable PTHrP." @default.
• W2103245862 created "2016-06-24" @default.
• W2103245862 creator A5000870045 @default.
• W2103245862 creator A5012336750 @default.
• W2103245862 creator A5023992858 @default.
• W2103245862 creator A5025650725 @default.
• W2103245862 creator A5049792647 @default.
• W2103245862 creator A5053293171 @default.
• W2103245862 creator A5053451402 @default.
• W2103245862 creator A5054972332 @default.
• W2103245862 creator A5061698687 @default.
• W2103245862 creator A5063351053 @default.
• W2103245862 creator A5069333376 @default.
• W2103245862 creator A5071040536 @default.
• W2103245862 creator A5071951173 @default.
• W2103245862 creator A5082866696 @default.
• W2103245862 creator A5090577453 @default.
• W2103245862 date "1999-10-01" @default.
• W2103245862 modified "2023-10-17" @default.
• W2103245862 title "Serum Parathyroid Hormone-Related Protein Levels and Response to Bisphosphonate Treatment in Hypercalcemia of Malignancy" @default.
• W2103245862 cites W1832685445 @default.
• W2103245862 cites W1883130365 @default.
• W2103245862 cites W1966461362 @default.
• W2103245862 cites W1971088941 @default.
• W2103245862 cites W1976749816 @default.
• W2103245862 cites W1979065270 @default.
• W2103245862 cites W1980576844 @default.
• W2103245862 cites W1980657360 @default.
• W2103245862 cites W1984421564 @default.
• W2103245862 cites W1986999259 @default.
• W2103245862 cites W1993486030 @default.
• W2103245862 cites W1996898338 @default.
• W2103245862 cites W1997364862 @default.
• W2103245862 cites W2002986403 @default.
• W2103245862 cites W2012837775 @default.
• W2103245862 cites W2014984275 @default.
• W2103245862 cites W2019392919 @default.
• W2103245862 cites W2024178909 @default.
• W2103245862 cites W2030415413 @default.
• W2103245862 cites W2032850918 @default.
• W2103245862 cites W2035935822 @default.
• W2103245862 cites W2037866115 @default.
• W2103245862 cites W2041856785 @default.
• W2103245862 cites W2044329713 @default.
• W2103245862 cites W2048509470 @default.
• W2103245862 cites W2048623091 @default.
• W2103245862 cites W2070617603 @default.
• W2103245862 cites W2082392098 @default.
• W2103245862 cites W2083551904 @default.
• W2103245862 cites W2089404694 @default.
• W2103245862 cites W2092249998 @default.
• W2103245862 cites W2094735395 @default.
• W2103245862 cites W2100197809 @default.
• W2103245862 cites W2105943764 @default.
• W2103245862 cites W2118054111 @default.
• W2103245862 cites W2128352396 @default.
• W2103245862 cites W2157679364 @default.
• W2103245862 cites W2205704527 @default.
• W2103245862 cites W2343554152 @default.
• W2103245862 cites W2417707286 @default.
• W2103245862 doi "https://doi.org/10.1210/jcem.84.10.6026" @default.
• W2103245862 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10522993" @default.
• W2103245862 hasPublicationYear "1999" @default.
• W2103245862 type Work @default.
• W2103245862 sameAs 2103245862 @default.
• W2103245862 citedByCount "36" @default.
• W2103245862 countsByYear W21032458622012 @default.
• W2103245862 countsByYear W21032458622014 @default.
• W2103245862 countsByYear W21032458622016 @default.
• W2103245862 countsByYear W21032458622020 @default.
• W2103245862 countsByYear W21032458622022 @default.
• W2103245862 crossrefType "journal-article" @default.
• W2103245862 hasAuthorship W2103245862A5000870045 @default.
• W2103245862 hasAuthorship W2103245862A5012336750 @default.
• W2103245862 hasAuthorship W2103245862A5023992858 @default.
• W2103245862 hasAuthorship W2103245862A5025650725 @default.
• W2103245862 hasAuthorship W2103245862A5049792647 @default.
• W2103245862 hasAuthorship W2103245862A5053293171 @default.
• W2103245862 hasAuthorship W2103245862A5053451402 @default.
• W2103245862 hasAuthorship W2103245862A5054972332 @default.
• W2103245862 hasAuthorship W2103245862A5061698687 @default.
• W2103245862 hasAuthorship W2103245862A5063351053 @default.
• W2103245862 hasAuthorship W2103245862A5069333376 @default.
• W2103245862 hasAuthorship W2103245862A5071040536 @default.
• W2103245862 hasAuthorship W2103245862A5071951173 @default.
• W2103245862 hasAuthorship W2103245862A5082866696 @default.
• W2103245862 hasAuthorship W2103245862A5090577453 @default.
• W2103245862 hasBestOaLocation W21032458621 @default.
• W2103245862 hasConcept C126322002 @default.
• W2103245862 hasConcept C134018914 @default.
• W2103245862 hasConcept C146562846 @default.
• W2103245862 hasConcept C159641895 @default.
• W2103245862 hasConcept C2776541429 @default.
• W2103245862 hasConcept C2777251235 @default.
• W2103245862 hasConcept C2779399171 @default.
• W2103245862 hasConcept C2779674975 @default.
• W2103245862 hasConcept C2780091579 @default.
• W2103245862 hasConcept C519063684 @default.

• next